External open innovation partner programPartnerYourAntibodies
Our R&D focuses on identifying and developing novel drugs for treating diseases with high unmet medical need. We are committed to innovation and to translating initial ideas from basic research into novel drugs. Bayer is dedicated to fostering collaborations with academic groups, start-up and biotech companies.
With our crowd-sourcing initiative PartnerYourAntibodies® we are looking for novel antibodies relating particularly to the fields of oncology, cardiology (including kidney diseases), hematology, ophthalmology as well as gynecology and addressing a specific target or pathway in a selective manner (functional activity). Successful applications will be assessed by us with regard to bioactivity.
If confirmed, we might initiate a joint antibody-exploration project with you, in which case you would receive substantial financial funding from Bayer to compensate for your research expenses. Such a collaboration would then be subject to the negotiation of a contract reflecting the interests of all parties involved.
Bayer is an experienced partner with a long tradition of successful and reliable global partnerships. If your antibody is selected for collaboration, you may in some cases be given an opportunity to use innovative technologies, complementary expertise and resources.
The submission is non-confidential and should include (if available) information on the antibody properties, including such biological data as :
- Used Library or host
- Amount available and Concentration
- Target, Pathway or Specificity (NO details on epitope)
- Assay used to test biological activity
- Affinity to target or ED50 in FACS analysis
For intellectual property reasons, please do NOT reveal the amino acid sequence, even if the sequence has already been published. Further, please do NOT provide the binding epitope.
The current submission period is open until June 30th 2016.
Your submission will be reviewed by senior scientists at Bayer. The outcome of our assessment is entirely at our discretion without any obligation to justify it or to give reasons.
If our assessment of your submission is positive, we want to find out more about your antibody or derivative and will contact you to determine the next steps. We might already provide you a reasonable monetary compensation for your effort at this stage.
If we are convinced by the data generated we would be interested in partnering with you to leverage the potential of the antibody by means of broader in vitro and in vivo characterization.
What is antibody-exploration?
Antibody-exploration is the process that corroborates the antibody's suitability by assessing its physico-chemical properties and pharmacological activities both in vitro and in vivo.
Can I submit antibody derivatives?
Beside antibodies, submission of derivatives such as Fab, scFv, minibody or similar is possible.
Who is eligible to apply?
Researchers from universities, other academic research institutes, or start-up and biotech companies from all over the world are invited to apply.
Will the information provided be considered confidential?
No, the information provided will not be considered confidential. We will use the information provided in the submission form for an initial evaluation. Before asking for confidential data we will agree a Confidential Disclosure Agreement (CDA) with you.
Who will review the proposals?
The proposals will be reviewed by experienced scientists at Bayer HealthCare
Can I submit a proposal on behalf of a group?
Yes, you can submit a proposal on behalf of a group. However, please name your collaborators/coworkers in the respective field. When concluding a Material Transfer Agreement (MTA) or a Confidential Disclosure Agreement (CDA) you should be aware of the ownership of your antibody; signatures of representatives of your institution/organization might be needed during the assessment period.
Can I submit polyclonal antibodies as well?
We are primarily interested in monoclonal antibodies.
Bayer is an innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants.
The company’s Pharmaceuticals Division invests considerable resources in the research and development of new drugs, with the aim of improving patients' quality of life and prolonging lives.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 8 main types of partnering programs with Academia.